Explore

Scientists Discover Gene That Could Enable Human Limb Regrowth

Scientists Discover Gene That Could Enable Human Limb Regrowth

Researchers from Wake Forest University, Duke University, and the University of Wisconsin-Madison have identified a set of genes that may one day allow humans to regrow limbs. The study, published in the Proceedings of the National Academy of Sciences, focused on axolotls, zebrafish, and mice, which are known for their regenerative abilities. The research revealed that genes SP6 and SP8 play a crucial role in limb regeneration across these species. Using CRISPR technology, scientists demonstrated that removing SP8 from axolotls hindered their ability to regenerate limb bones. Similarly, mice showed regeneration issues when SP6 and SP8 were absent. The study suggests that future therapies could mimic these genetic mechanisms to promote human limb regrowth.

University of Tokyo Researchers Uncover Massive Hydraulic Jump on Venus

University of Tokyo Researchers Uncover Massive Hydraulic Jump on Venus

Researchers from the University of Tokyo, led by Professor Takeshi Imamura, have identified a massive hydraulic jump on Venus, explaining a mysterious 6,000-kilometer-wide atmospheric wave. This discovery, published in the Journal of Geophysical Research: Planets, reveals that the wave is the result of the largest hydraulic jump ever observed in the solar system. A hydraulic jump is a sudden change in the flow of a fluid, where it slows down and deepens, similar to water spreading out in a sink. On Venus, this phenomenon occurs as the atmospheric wave moves eastward through the lower cloud layers, reaching a critical point where its flow becomes unstable. This instability generates a strong vertical updraft, carrying sulfuric acid vapor high into the atmosphere and forming the enormous wave.

CBS LA Meteorologist Marina Jurica Hosts Crohn's and Colitis Foundation Walk in Irvine

CBS LA Meteorologist Marina Jurica Hosts Crohn's and Colitis Foundation Walk in Irvine

CBS LA Meteorologist Marina Jurica participated in hosting the Crohn's and Colitis Foundation Walk in Irvine. The event took place on a Saturday and aimed to raise awareness and funds for Crohn's disease and ulcerative colitis, which are chronic inflammatory conditions of the gastrointestinal tract. The walk is part of a series of events organized by the Crohn's and Colitis Foundation to support research and provide resources for those affected by these conditions. Jurica's involvement highlights the importance of community engagement and media support in promoting health-related causes.

New Study Suggests Humans May Have Hidden Regenerative Powers

New Study Suggests Humans May Have Hidden Regenerative Powers

Researchers at Texas A&M University have discovered a potential method to regenerate skeletal and connective tissue in mammals, challenging the long-held belief that humans cannot regrow lost body parts. The study, published in Nature Communications, involved a two-step treatment using fibroblast growth factor 2 (FGF2) and bone morphogenetic protein 2 (BMP2) to redirect the body's natural healing process from scarring to regeneration. This approach led to the formation of blastema-like structures, which are typically absent in mammals, and resulted in the regrowth of bone, joint structures, and ligaments, albeit imperfectly.

University of Illinois Chicago Develops Bacteria-Inspired Cancer Therapy Targeting Tumor Energy Production

University of Illinois Chicago Develops Bacteria-Inspired Cancer Therapy Targeting Tumor Energy Production

Researchers at the University of Illinois Chicago have developed a novel cancer therapy that utilizes a strategy inspired by bacteria residing within tumors. This approach targets the energy production mechanisms of cancer cells rather than attacking the cells directly. The therapy involves a lab-made peptide called aurB, derived from a bacterial protein, which disrupts the mitochondria within cancer cells, thereby hindering their energy supply. In prostate cancer models, the therapy showed significant results, especially when combined with radiation, a standard treatment. The findings, published in Signal Transduction and Targeted Therapy, highlight the potential of targeting mitochondria, the cell's energy factories, as an effective cancer treatment strategy.

Scientists Develop Lab-Grown Insulin Cells to Reverse Diabetes in Mice

Scientists Develop Lab-Grown Insulin Cells to Reverse Diabetes in Mice

Researchers in Sweden have made significant progress in the treatment of type 1 diabetes by developing a method to create insulin-producing cells from human stem cells. This breakthrough, published in Stem Cell Reports, demonstrates that these lab-grown cells can effectively control blood sugar levels and even reverse diabetes in mice. Type 1 diabetes occurs when the immune system destroys the pancreas's insulin-producing cells, leading to high blood sugar levels. The new method reliably produces high-quality insulin-producing cells from multiple human stem cell lines, potentially paving the way for patient-specific cell therapies that could reduce immune rejection. The cells, when transplanted into diabetic mice, restored the animals' ability to regulate blood sugar over time.

Constipation Drug Lubiprostone Shows Promise in Protecting Kidney Function

Constipation Drug Lubiprostone Shows Promise in Protecting Kidney Function

Researchers at Tohoku University have discovered that lubiprostone, a drug commonly used to treat constipation, may slow the decline of kidney function in patients with moderate chronic kidney disease (CKD). In a clinical trial involving 150 patients, those who received lubiprostone showed a slower decline in kidney function compared to those given a placebo. The study suggests that the drug's benefits may be linked to its effects on the gut microbiome, which in turn supports mitochondrial function and reduces kidney damage. This finding opens new avenues for treating CKD by targeting gut health.

Advancements in In Vitro Cardiac Models Enhance Drug Evaluation Processes

Advancements in In Vitro Cardiac Models Enhance Drug Evaluation Processes

Advancements in In Vitro Cardiac Models Enhance Drug Evaluation Processes

Scientists Isolate Antibodies to Combat Measles Amid Rising U.S. Cases

Scientists Isolate Antibodies to Combat Measles Amid Rising U.S. Cases

Researchers have identified four potent antibodies from the blood of a vaccinated individual that could lead to a new treatment for measles, a disease that is experiencing a resurgence in the United States. Despite the availability of a highly effective vaccine since the 1960s, declining vaccination rates have led to significant outbreaks. The newly discovered antibodies could provide a therapeutic option for those exposed to the virus, particularly for individuals who are immunocompromised or too young to be vaccinated. The study, led by Erica Ollmann Saphire of the La Jolla Institute for Immunology, highlights the potential of these antibodies to reduce viral loads in infected individuals, although it is not intended to replace vaccination.

Fujifilm Unveils New Screening Platform for Cyclic Peptides Targeting Membrane Proteins

Fujifilm Unveils New Screening Platform for Cyclic Peptides Targeting Membrane Proteins

Fujifilm Unveils New Screening Platform for Cyclic Peptides Targeting Membrane Proteins

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in May 2026

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in May 2026

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in May 2026

Delcath Systems Presents New Data on Liver Cancer Treatment at ESMO

Delcath Systems Presents New Data on Liver Cancer Treatment at ESMO

Delcath Systems, Inc. has presented new data at the ESMO Breast Cancer Congress 2026 on the use of percutaneous hepatic perfusion with melphalan (M-PHP) for treating liver-dominant metastatic breast cancer. The retrospective analysis involved 15 patients and evaluated the feasibility, safety, and tumor response of the treatment. The study found that 60% of patients achieved a hepatic partial response, with a median overall survival of 6 months. The treatment was associated with significant adverse events, including bone marrow suppression and neutropenic-related infections, but these were typically resolved within a week.